Mitsubishi Tanabe Pharma America, Inc. (MTPA) has recently presented one abstract in amyotrophic lateral sclerosis (ALS) at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting, being held in New Orleans, from April 15-18, 2024.

"Understanding healthcare resource utilization is crucial for assessing RADICAVA ORS (edaravone) cost-effectiveness, optimizing healthcare delivery, improving patient outcomes and guiding healthcare planning," said Gustavo A. Suarez Zambrano, MD, Vice President of Medical Affairs at MTPA.

"Our data demonstrate not only the economic value of RADICAVA ORS but also its potential to improve efficiency and reduce healthcare costs. These real-world results underscore our commitment to provide innovative treatments that make a meaningful difference in patient care and healthcare outcomes," he added.

MTPA's poster will be on display on Tuesday, April 16 from 11 am - 6 pm and Wednesday, April 17 from 9-11:30 am in the Expo Hall. The presentation will include a preliminary analysis of demographics, characteristics and healthcare resource utilization data, as part of Optum's de-identified Clinformatics Data Mart (CDM).

The US Food and Drug Administration (FDA) approved RADICAVA (edaravone) on May 5, 2017, and the oral formulation RADICAVA ORS (edaravone) on May 12, 2022, for the treatment of amyotrophic lateral sclerosis (ALS). RADICAVA is administered in 28-day cycles by intravenous (IV) infusion. It takes 60 minutes to receive each 60 mg dose. For the initial cycle, the treatment is infused daily for 14 consecutive days, followed by a two-week drug-free period. All cycles thereafter are infused daily for 10 days within 14 days, followed by a two-week drug-free period. RADICAVA ORS is taken daily for 14 consecutive days followed by a 14-day drug-free period for the initial treatment cycle.

For subsequent treatment cycles, RADICAVA ORS is taken for 10 days within 14 days followed by a 14-day drug-free period. RADICAVA ORS should be taken in the morning after overnight fasting. Patients should not eat or drink (except water) within one hour after taking RADICAVA ORS.

Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and commercialized in the US by Mitsubishi Tanabe Pharma America, Inc. (MTPA).